ALMIRALL, S.A. «...678910...» Page 6 out of 16 03/02/2023 13:43 ALMIRALL, S.A. On business and financial situation Almirall acquires Physiorelax® portfolio from DFT El Globo Register number: 20277 10/01/2023 17:37 ALMIRALL, S.A. Other relevant information Presentation: 41st Annual J.P. Morgan Healthcare Conference 2023 Register number: 19953 04/01/2023 11:52 ALMIRALL, S.A. Liquidity and counterparty agreements Operaciones del contrato de liquidez durante el cuarto trimestre de 2022 Register number: 19872 18/11/2022 07:53 ALMIRALL, S.A. On business and financial situation Almirall perpetually licenses Motilex® to Teofarma in Italy Register number: 19255 10/11/2022 07:58 ALMIRALL, S.A. On business and financial situation Almirall announces that will webcast a conference to introduce and explain the results for the third quarter of 2022 Register number: 19138 10/11/2022 07:54 ALMIRALL, S.A. On business and financial situation Almirall files Third Quarter results presentation for 2022 Register number: 19137 28/10/2022 07:50 ALMIRALL, S.A. On business and financial situation Almirall announces EMA acceptance for filing of Marketing Authorization Application (MAA) for lebrikizumab in atopic dermatitis Register number: 18925 04/10/2022 09:51 ALMIRALL, S.A. Liquidity and counterparty agreements Operaciones del contrato de liquidez durante el tercer trimestre de 2022 Register number: 18534 29/09/2022 08:02 ALMIRALL, S.A. Other relevant information Almirall and Simcere enter into a licensing agreement for IL-2-mu-Fc Register number: 18451 08/09/2022 14:16 ALMIRALL, S.A. On business and financial situation Almirall: Lebrikizumab Dosed Every Four Weeks Maintained Durable Skin Clearance in Phase 3 Monotherapy Atopic Dermatitis Trials Register number: 18149 Page 6 out of 16 «...678910...»